trending Market Intelligence /marketintelligence/en/news-insights/trending/vars3pwfa3xed7ul7n9rda2 content esgSubNav
In This List

Bavarian Nordic's smallpox vaccine proves effectiveness in phase 3 study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Bavarian Nordic's smallpox vaccine proves effectiveness in phase 3 study

Bavarian Nordic A/S said the phase 3 trial of its nonreplicating smallpox vaccine Imvamune met its main goals, showing the drug's effectiveness compared to a current U.S.-licensed replicating smallpox vaccine.

The study, conducted in 440 volunteers, demonstrated Imvamune's efficacy and statistically superior immune response in comparison to Acam2000. Based on the results, Imvamune stimulated peak neutralizing antibodies twofold higher than Acam2000.

The company plans to submit a biologics license application for the vaccine in the second half of 2018.

Bavarian Nordic funded the study in whole or in part using federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority.